Executive Summary
CMS reopened the National Coverage Analysis for TAVR (CAG-00430R2), the most consequential US structural heart policy event of 2026 — and it lands the same week echo and CT data continue chipping at pre-TAVR workflow orthodoxies. RV-PA uncoupling by TAPSE/PAPs <0.29 mm/mmHg predicted combined pre- and post-capillary PH and doubled 2-year mortality in 667 TAVR patients, and a CTA-first coronary strategy spared invasive angiography in 73% of patients with equivalent long-term survival over 61.7 months (N=307, single-center). Boston Scientific closed at $46.73, down 49% over six months, decoupling from the sector on Watchman/EP concerns unrelated to valves — which breaks the case for reading structural heart demand off BSX price action.
- CMS opened tracking sheet CAG-00430N and the reconsideration memo alongside it, formally reopening TAVR coverage.
- TAPSE/PAPs <0.29 identified combined-PH with AUC 0.740 and stratified 2-year mortality in 667 pre-TAVR patients.
- CTA-first pre-TAVR coronary workup avoided invasive angiography in 73% with no survival penalty at median 61.7 months, though a non-significant trend toward more late catheterization persisted (HR 2.47).
- A systematic review of 25 studies confirmed women have better long-term TAVR survival despite higher vascular complication and major bleeding rates.
- M-TEER under argatroban successfully treated acute severe MR with suspected HIT when cardiopulmonary bypass was prohibitive (two PASCAL Ace implants, MR reduced to trivial).
What to watch: the CMS TAVR NCD public comment window and any signals on hospital volume floors, heart team requirements, or bicuspid coverage — the last reconsideration cemented the two-surgeon rule that industry has been trying to unwind ever since.
Aortic Valve (TAVR/TAVI)
Pre-procedural risk stratification took two concrete steps forward this week. In 667 consecutive TAVR patients at a single Italian center, an echo-derived TAPSE/PAPs ratio of 0.29 mm/mmHg discriminated combined pre- and post-capillary PH (AUC 0.740, sensitivity 72%, specificity 60%) and identified a cohort with significantly worse 2-year all-cause mortality (log-rank p=0.026, retrospective, single-center). Patients below that threshold warrant right heart catheterization before TAVR, not after. Neither ACC/AHA 2020 nor ESC 2025 specify a TAPSE/PAPs cutoff for pre-TAVR workup; both defer to Heart Team judgment on PH evaluation, leaving this threshold without guideline anchoring until prospective validation arrives.
A CTA-first coronary strategy in 307 patients (single-center, non-randomized) delivered equivalent survival at 61.7 months versus ICA-first while avoiding invasive angiography in 73% (HR 0.88 for mortality). A non-significant signal toward more late post-TAVR catheterization (HR 2.47) deserves prospective testing before CTA-first becomes the default workflow. ESC 2025 recommends coronary assessment prior to valve intervention (Class I) but does not specify modality; ACC/AHA 2020 similarly leaves CTA versus ICA to institutional discretion.
A systematic review of 25 studies (2015–2025) confirmed the persistent sex paradox: women have higher short-term vascular and bleeding complications but better long-term survival than men after TAVR. ACC/AHA 2020 treats sex as a factor in shared decision-making but not in valve type or access selection; ESC 2025 is similarly silent on sex-specific access strategies despite the durable disparity in outcomes.
Mitral Valve (MitraClip, PASCAL, TMVR)
M-TEER extended into rescue territory where surgery is off the table. A JACC Case Reports account describes acute severe MR from chordal rupture with cardiogenic shock, IABP support, and clinically suspected HIT (4Ts score 6, positive PF4/heparin antibody). Two PASCAL Ace implants deployed under argatroban infusion reduced MR from severe to trivial without thrombotic or bleeding complications, enabling immediate IABP removal. This is anecdotal, N=1, and involves industry devices — but the pathway is clinically real: when heparin-based cardiopulmonary bypass is prohibitive, M-TEER is the only structural option. ACC/AHA 2020 reserves TEER for primary MR at Class IIa in high surgical risk with suitable anatomy; ESC 2025 aligns. Neither guideline addresses acute chordal rupture with HIT explicitly, but both frameworks classify this presentation as prohibitive surgical risk, and the surgical literature offers no clean bailout — bivalirudin-based CPB for HIT carries mortality well above elective repair in the emergent setting.
Tricuspid Valve (TriClip, TTVR)
A state-of-the-art review in JRSM Cardiovascular Disease frames transcatheter tricuspid therapy as a low-risk alternative to surgery, citing historical isolated TV surgery in-hospital mortality up to 10% in selected cases. That framing tracks the 2025 ESC guideline upgrade of transcatheter TV treatment to Class IIa (LOE A) for high-risk symptomatic severe TR — a category ACC/AHA 2020 did not address because TRILUMINATE, Tri.Fr, and TRISCEND II had not yet reported. The surgical comparator is weaker than the review implies: contemporary surgical series with earlier referral show mortality well below 10%, and the review risks locking in an outdated benchmark to justify transcatheter expansion. A Cureus case of torrential TR with complete leaflet degeneration and right atrial ventricularization — deemed unsuitable for both surgery and transcatheter intervention — illustrates the far end of the referral curve: patients who arrive after the RV has failed are salvageable by neither approach. Earlier referral remains the field's most pressing unsolved problem in tricuspid disease.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. The week's transcatheter findings — RV-PA uncoupling, CTA-first workup, PASCAL under argatroban, TR review — sit against an unchanged surgical benchmark: SAVR remains the ESC 2025 Class I recommendation for AS below age 70 with low surgical risk, and MV repair remains preferred for primary MR whenever a durable result is achievable. On BAV, ESC 2025 and ACC/AHA 2020 hold the same conservative posture (Class IIb for TAVI in BAV), and none of this week's sources move that needle.
Regulatory & Policy
[NOTABLE] CMS reopened the TAVR National Coverage Determination on CAG-00430R2, with the tracking sheet published Aug 2. The 2019 reconsideration removed the trial-participation requirement and kept the two-surgeon TAVR-eligibility rule and hospital/operator volume floors. Industry priorities this round: loosening the two-surgeon requirement, formalizing bicuspid coverage without the CoreValve US Pivotal-era caveats, and codifying same-day discharge. The clinical community's priorities: keeping heart team infrastructure intact as TAVR volumes migrate to lower-risk, younger, longer-lived patients where guideline evidence is thinnest.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $86.07, -0.98% on the day, +4.14% over six months
- Market cap $49.6B, trailing P/E 51.2, forward P/E 25.5, beta 0.85, 52-week range $72.30–$96.29
- Analyst target $100.96 (26 analysts, range $84–$110), consensus buy
- Next earnings Oct 29 (EPS est $0.74, revenue est $1.68B)
Edwards is the cleanest read on structural heart in this basket — SAPIEN plus PASCAL plus EVOQUE — and the modest six-month gain reflects a market pricing in the ESC 2025 TAVI-at-70 shift and TRISCEND II data without pricing in near-term US coverage expansion. The CMS NCD reopening is the next binary.
Medtronic (MDT)
- Close $85.39, -0.37% on the day, -15.43% over six months
- Trailing P/E 22.9, forward P/E 13.3, beta 0.58, 52-week range $73.31–$106.33
- Analyst target $98.44 (25 analysts, range $78–$121), consensus buy
- Next earnings Sep 1 (EPS est $1.39, revenue est $9.55B)
Evolut owns the self-expanding half of TAVR volume, and the six-month drawdown reflects diabetes/neuromod overhang more than structural heart weakness. DEDICATE and Evolut Low Risk 5-year data support the franchise; the CMS reconsideration matters more for MDT than for EW because Evolut skews slightly older.
Abbott (ABT)
- Close $105.70, +0.09% on the day, -2.09% over six months
- Market cap $182.9B, trailing P/E 34.2, forward P/E 17.4, beta 0.61, 52-week range $81.97–$137.49
- Analyst target $118.42 (24 analysts, range $103–$135), consensus buy
- Next earnings Oct 14 (EPS est $1.42, revenue est $12.99B)
MitraClip and TriClip are the structural franchise; the ESC 2025 upgrade of TEER for ventricular SMR to Class I (LOE A) is a tailwind that hasn't fully surfaced in the multiple. Diagnostics normalization remains the dominant story for the whole company.
Boston Scientific (BSX)
- Close $46.73, +1.59% on the day, -49.13% over six months
- Market cap $69.5B, trailing P/E 18.9, forward P/E 13.6, beta 0.58, 52-week range $42.20–$109.50
- Analyst target $62.69 (29 analysts, range $44–$94), consensus buy
- Next earnings Oct 21 (EPS est $0.81, revenue est $5.26B)
The 49% six-month drawdown is EP and Watchman-driven and has minimal read-through to the Acurate neo2/Prime aortic franchise. Analyst target dispersion ($44–$94) is unusually wide for a large-cap medtech, reflecting real disagreement about the FARAPULSE trajectory rather than valve exposure.
Anteris Technologies (AVR.AX)
- Close A$11.29, flat on the day, +31.13% over six months
- Market cap A$1.1B, forward P/E -5.18, beta 0.73, 52-week range A$5.00–A$15.47
- Single analyst target A$13.00, no consensus recommendation
DurAVR next-gen TAVR remains pre-pivotal; the 31% six-month gain reflects biological valve durability narrative traction rather than clinical inflection. Watch for pivotal design updates and any partnership signals.
Sector outlook: the structural heart cohort is bifurcating. EW, MDT, and ABT trade on clinical-evidence tailwinds (ESC 2025, EARLY TAVR, RESHAPE-HF2, TRILUMINATE) that will take multiple quarters to convert to volume. BSX is trading on non-valve dynamics. The CMS NCD reopening is the next real catalyst for the whole basket.
Clinical Trial Updates
Aortic
- NCT07739316 — Systematic Ambulatory ECG Monitoring Following TAVI. Status: not yet recruiting. Enrollment: 754. Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec / Université Laval. Addresses the persistent conduction-disturbance question post-TAVR, directly relevant given BAV data showing 6.5% new third-degree AV block after SAVR in BAV-AS patients.
- NCT07738575 — Same-Day Versus Standard Hospital Discharge After TAVI (HOME-TAVI). Status: not yet recruiting. Enrollment: 764. Sponsor: Hospital Clínic de Barcelona. Same-day discharge is a stated industry priority in the CMS comment process; a randomized 764-patient dataset would materially shift the guideline conversation.
The landmark studies shaping current practice — EARLY TAVR (asymptomatic AS, now driving ESC Class IIa early intervention), PARTNER 3 and Evolut Low Risk (5–10 year durability), DEDICATE (investigator-initiated low-risk), COAPT and RESHAPE-HF2 (ventricular SMR TEER), and TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II (tricuspid) — underpin the ESC 2025 vs ACC/AHA 2020 divergences flagged throughout this edition.
The CMS TAVR NCD public comment window opens the highest-stakes structural heart policy debate since the 2019 reconsideration. Every finding in this edition — RV-PA uncoupling, CTA-first workflows, same-day discharge trials, sex-specific outcomes — will surface as evidence in the coming comment letters.